This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia.
This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia. NTX-253 is an investigational drug being developed for the treatment of schizophrenia. The study will consist of a single ascending dose (SAD - Part 1a) phase which will include a food effect cohort, and a cerebrospinal fluid (CSF - Part 1b) cohort in healthy volunteers. Participants will receive a single dose of either oral NTX-253 or placebo. The multiple ascending dose (MAD - Part 2) phase will follow. In Part 2, participants will be dosed for 10 consecutive days with either NTX-253 or placebo. Each phase will include sequential escalating doses in healthy volunteers. Two cohorts in the MAD phase will include stable schizophrenic adult participants who have had antipsychotic medication withdrawn for up to 8 days prior to dosing with NTX-253.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
73
Collaborative Neuroscience Research, LLC - CenExel
Los Alamitos, California, United States
RECRUITINGNumber of reported Adverse Events
Safety and tolerability will be assessed by the incidence and severity of treatment-emergent adverse events.
Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).
Number of Adverse Events of Special Interest (AESI)
Safety and tolerability will be assessed by the incidence and severity of AESIs.
Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).
Number of dose limiting treatment emergent adverse events (TEAE)
Safety and tolerability will be assessed by the incidence and severity of serious or dose limiting TEAEs.
Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).
Vital Signs: Change in blood pressure
Blood pressure measurements
Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).
Vital Signs: Change in temperature
Oral temperature measurement
Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).
Vital Signs: Change in respiratory rate
Respiratory rate (number of breaths per minute) measurements
Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).
Vital Signs: Change in heart rate
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pulse measurements.
Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).
Change in physical examination
Investigator will perform complete physical exam and document any clinically significant conditions.
Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).
Clinical Laboratory Tests
Hematology, serum chemistry, urinalysis, and coagulation tests.
Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).
Maximum observed plasma concentration (Cmax) [Pharmacokinetics]
Samples will be collected periodically until: * 72 hours after a single dose with optional samples collected at 96, 120, 144, and 168 post-dose. * 72 hours after multiple doses with optional samples collected at 96, 120, 144, and 168 hours after the last dose.
Time frame: From baseline until up to 168 hours after a single dose, or until up to 168 hours after the last dose in the multiple dose cohorts.
Time of Cmax (tmax) [Pharmacokinetics]
Samples will be collected periodically until: * 72 hours after a single dose with optional samples collected at 96, 120, 144, and 168 post-dose. * 72 hours after multiple doses with optional samples collected at 96, 120, 144, and 168 hours after the last dose.
Time frame: From baseline until up to 168 hours after a single dose, or until up to 168 hours after the last dose in the multiple dose cohorts.
Apparent terminal half-life (t1/2)
Samples will be collected periodically until: * 72 hours after a single dose with optional samples collected at 96, 120, 144, and 168 post-dose. * 72 hours after multiple doses with optional samples collected at 96, 120, 144, and 168 hours after the last dose.
Time frame: From baseline until up to 168 hours after a single dose, or until up to 168 hours after the last dose in the multiple dose cohorts.
Amount of unchanged drug excreted in urine (Ae) [urinary excretion)
Samples will be collected in select cohorts from baseline until 72 hours after a single dose, or at baseline and on the last dosing day after multiple dose administrations.
Time frame: From baseline until 72 hours after a single dose, or until the last dosing on Day 10 in the multiple dose cohort.
Percent of dose excreted as unchanged drug in urine (Ae%) [urinary excretion]
Samples will be collected in select cohorts from baseline until 72 hours after a single dose, or at baseline and on the last dosing day after multiple dose administrations.
Time frame: From baseline until 72 hours after a single dose, or until the last dosing on Day 10 in the multiple dose cohort.
Renal clearance (Clr) [urinary excretion]
Samples will be collected in select cohorts from baseline until 72 hours after a single dose, or at baseline and on the last dosing day after multiple dose administrations.
Time frame: From baseline until 72 hours after a single dose, or until the last dosing on Day 10 in the multiple dose cohort.
Maximum observed CSF concentration (Cmax, CSF) [Pharmacokinetics]
CSF samples will be collected at periodic intervals until 12 hours after a single dose in a single dose CSF cohort.
Time frame: From baseline until 12 hours after a single dose.
Time corresponding to Cmax (Tmax, CSF) [Pharmacokinetics]
CSF samples will be collected at periodic intervals until 12 hours after a single dose in a single dose CSF cohort.
Time frame: From baseline until 12 hours after a single dose.
QT/QTc potential interval prolongation and plasma concentration
Electrocardiograms (ECGs) will be collected to assess the potential for QT/QTc interval prolongation and ΔQTc as measured by: • Change from baseline in cardiac measurements
Time frame: From baseline until 72 hours post-dose in the single dose cohorts, then from baseline until Day 13 in the multiple dose cohorts.